Skip to content
Avobenzone
Anthelios, Capital Soleil, Shade Uvaguard (avobenzone) is a small molecule pharmaceutical. Avobenzone was first approved as Shade uvaguard on 1992-12-07. It is used to treat photosensitivity disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil (discontinued: Shade uvaguard)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Ecamsule
+
Octocrylene
Tradename
Company
Number
Date
Products
CAPITAL SOLEIL 15L'OréalN-021501 OTC2006-10-02
1 products, RLD, RS
ANTHELIOS SXL'OréalN-021502 OTC2006-07-21
1 products, RLD, RS
Avobenzone
+
Ecamsule
+
Octocrylene
+
Titanium dioxide
Tradename
Company
Number
Date
Products
ANTHELIOS 20L'OréalN-021471 OTC2006-10-05
1 products, RLD, RS
ANTHELIOS 40L'OréalN-022009 OTC2008-03-31
2 products, RLD, RS
Avobenzone
+
Octinoxate
+
Oxybenzone
Tradename
Company
Number
Date
Products
SHADE UVAGUARDBayerN-020045 DISCN1992-12-07
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
defense total high protection spf 50 no color daily non-greasy face protectionOTC monograph final2023-06-20
la roche posay face body anthelios spf 60 melt in milk fast absorbing, velvety finish for all skin types with cell-oc shield xlOTC monograph not final2022-12-29
vichy laboratoires capital soleil 50 daily antiaging face sunscreen broad spectrum spf 50 water resistant 80 minutesOTC monograph not final2022-02-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
photosensitivity disorders—D010787L57.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.18——1113
AnesthesiaD000758———123
Neuromuscular blockadeD019148———112
Postoperative nausea and vomitingD020250EFO_0004888———112
Conduction anesthesiaD000765———1—1
Prostatic hyperplasiaD011470EFO_0000284N40———1—1
Retinal diseasesD012164HP_0000479H35.9———1—1
MyoclonusD009207HP_0001336G25.3———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PremedicationD011292—22——2
Intratracheal intubationD007442—22——2
Muscle relaxationD009126—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Radical mastectomyD01540911———1
Intraocular pressureD007429—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179————11
Male breast neoplasmsD018567————11
Swine diseasesD013553————11
Urologic diseasesD014570N39.9————11
Lacrimal duct obstructionD007767————11
Inguinal herniaD006552HP_0000023K40————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAVOBENZONE
INNavobenzone
Description
Avobenzone is a member of dihydrochalcones.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C(=O)CC(=O)c2ccc(C(C)(C)C)cc2)cc1
Identifiers
PDB—
CAS-ID70356-09-1
RxCUI45045
ChEMBL IDCHEMBL1200522
ChEBI ID—
PubChem CID51040
DrugBankDB09495
UNII IDG63QQF2NOX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 399 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,074 adverse events reported
View more details